HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.165
+0.005 (+3.13%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.160
Open0.165
Bid0.160 x 0
Ask0.165 x 0
Day's Range0.160 - 0.165
52 Week Range0.075 - 0.200
Volume2,501,592
Avg. Volume15,935,913
Market Cap217.737M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.009
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • FSD Pharma Surpasses One Billion Shares Traded and Makes History With Annual CSE Volume Trading Record in Less Than Two Months
    CNW Group2 days ago

    FSD Pharma Surpasses One Billion Shares Traded and Makes History With Annual CSE Volume Trading Record in Less Than Two Months

    CSE: HUGE OTC: FSDDF TORONTO , June 20, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTC: FSDDF), is pleased to report that it has traded over one Billion Class ...

  • FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures
    CNW Group3 days ago

    FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures

    CSE:HUGE OTC:FSDDF TORONTO , July 19, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (CSE:HUGE) (OTC:FSDDF) today announced that its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma") ...

  • FSD Pharma Inc. announces acquisition to expand in Newfoundland for production and sales
    CNW Group10 days ago

    FSD Pharma Inc. announces acquisition to expand in Newfoundland for production and sales

    TORONTO, July 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News) (OTC:FSDDF - News) is pleased to announce a binding agreement to purchase 51% of Atlantic Island Cannabis Inc. (to be renamed FSD Atlantic Pharma Inc.) effective July 4, 2018. The agreement involves a strategic investment of $40 million to drive production and sales of legal cannabis in the province of Newfoundland.

  • FSD Pharma Announces Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms
    CNW Group12 days ago

    FSD Pharma Announces Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms

    TORONTO, July 10, 2018 /CNW/ - FSD Pharma (CSE:HUGE.CN - News) (OTC:FSDDF - News) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its 620,000 square foot facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").

  • FSD Pharma Breaks All-Time Monthly Stock Volume Trading Record
    CNW Group17 days ago

    FSD Pharma Breaks All-Time Monthly Stock Volume Trading Record

    /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/ CSE: HUGE TORONTO , July 5, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE), is pleased ...

  • FSD Pharma Inc. announces $55 million dollar indoor cannabis grow partnership expansion at its Cobourg facility
    CNW Group19 days ago

    FSD Pharma Inc. announces $55 million dollar indoor cannabis grow partnership expansion at its Cobourg facility

    TORONTO, July 3, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News) is pleased to provide an update on the progress of the joint venture between its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma) and Auxly Cannabis Group Inc. (TSX.V – XLY) ("Auxly"). The first phase of the buildout of the FV Pharma facility (the "Facility") in Cobourg, Ontario has been approved in an updated construction and development budget provided by Auxly. Of the current 620,000 square feet of building space available, 220,000 square feet will be developed and fully funded.

  • GlobeNewswire19 days ago

    Auxly Provides Development Update on the FV Pharma Joint Venture

    Auxly Cannabis Group Inc. (XLY.V) ("Auxly" or the "Company") is pleased to provide the following construction development update on the joint venture with FV Pharma Inc. (“FV Pharma”), a wholly-owned subsidiary of FSD Pharma Inc. (CSE:HUGE) at the former Kraft food-production facility (the “Facility”) located in Cobourg, Ontario. The Facility hosts an initial 620,000 square feet of building space, a portion of which is currently licensed for cultivation pursuant to the Access to Cannabis for Medical Purposes Regulations, and can support additional expansion capacity of approximately 3,800,000 square feet on the existing property, pending completion of all phases of the project. Pursuant to the updated and approved construction budget, Auxly will contribute $55,000,000 to develop the first phase of the project.

  • FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board
    CNW Group26 days ago

    FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board

    TORONTO , June 26, 2018 /CNW/ - FSD Pharma Inc.  ("FSD Pharma" or the "Company") (CSE:HUGE), announced today the appointment of Dr. Zohar Koren as Head of the Company's Scientific Advisory ...

  • CNW Group27 days ago

    FSD Pharma Breaks All-Time Weekly Stock Volume Trading Record

    /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/ CSE: HUGE TORONTO , June 25, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE), is pleased ...

  • FSD Pharma Inc. Welcomes Official Passing of Cannabis Act in Canada
    CNW Grouplast month

    FSD Pharma Inc. Welcomes Official Passing of Cannabis Act in Canada

    TORONTO, June 22, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News), welcomes the official passing of Bill C-45, the Cannabis Act in Canada. Bill C-45 formally received Royal Assent Thursday morning in Canada's Parliament. The bill officially becomes law on October 17, 2018 when retail sales begin, according to an announcement by Canada's federal government.

  • FSD Pharma Inc. Announces Appointment of Chief Commercial Officer
    CNW Grouplast month

    FSD Pharma Inc. Announces Appointment of Chief Commercial Officer

    TORONTO, June 21, 2018 /CNW/ - Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News), is pleased to announce the appointment of Mr. Michael Ash as the Chief Commercial Officer of FV Pharma Inc. ("FV Pharma"), a wholly-owned subsidiary of the Company. Michael Ash brings a wealth of pharmaceutical industry expertise to FV Pharma in the areas of domestic and international sales and distribution, product and brand development, and product packaging.

  • FSD Pharma Inc. Announces a Partnership Agreement with Cannara Biotech Inc. to Allow for Indoor Grow Space to Increase to a Combined 1,245,000 Square Feet
    CNW Grouplast month

    FSD Pharma Inc. Announces a Partnership Agreement with Cannara Biotech Inc. to Allow for Indoor Grow Space to Increase to a Combined 1,245,000 Square Feet

    TORONTO, June 19, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "The Company") (CSE:HUGE.CN - News), announced the signing of a partnership agreement between FV Pharma Inc. ("FV Pharma"), a wholly-owned subsidiary of the Company, and Cannara Biotech Inc. ("Cannara") effective May 31, 2018. The agreement creates the ability for the Company to  become the largest indoor medical cannabis growing operation in North America.

  • FSD Pharma Inc. Added to the CSE 25 Composite Index
    CNW Grouplast month

    FSD Pharma Inc. Added to the CSE 25 Composite Index

    TORONTO, June 18, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News) has been added to the CSE 25 Composite Index, effective after the close on Friday, June 15, 2018. The Company met index entry requirements and bypassed the typical seasoning period for a new entrant due to its placement in the top quartile of the Index. The Company is pleased to see FSD recognized so quickly as a "cream of the crop" new entrant on the Index.

  • FSD Pharma Inc. Announces Appointment of New Director
    CNW Grouplast month

    FSD Pharma Inc. Announces Appointment of New Director

    TORONTO, June 14, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE.CN - News), is pleased to announce the appointment of Mr. Anthony Durkacz to its Board of Directors, effective immediately. Mr. Durkacz is currently a Director and Executive Vice President at First Republic Capital Corp. since January 2014. First Republic Capital Corp. has acted as the exclusive agent of the Company and has raised approximately $53,000,000.00 of equity capital to date.

  • GlobeNewswirelast month

    FSD Pharma Inc. Grants Stock Options to Certain Directors

    FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE), a Canadian cannabis company focused on building the world’s largest indoor hydroponic cultivation and processing facility through its wholly owned subsidiary FV Pharma Inc. ("FV"), a Licensed Producer ("LP") pursuant to the Access to Cannabis for Medical Purposes Regulations ("ACMPR"), held its first meeting of the board of directors of the Company (the "Board") on June 12, 2018 since becoming a public listed issuer on the CSE. The Company announces that pursuant to its Stock Option Plan, the Board approved the grant of 9,000,000 stock options for class B subordinate voting shares of the Company (the "Options") to certain directors of the Company.

  • FSD Pharma breaks all-time weekly volume trading record
    CNW Grouplast month

    FSD Pharma breaks all-time weekly volume trading record

    /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/ CSE: HUGE TORONTO , June 7, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE), is pleased ...

  • CNW Group2 months ago

    FSD Pharma secures exclusive rights in Canada for line of proprietary products and premium access to cannabinoid science research platform in Israel

    TORONTO, June 6, 2018 /CNW/ - FSD Pharma Inc. (the "Company") (CSE:HUGE.CN - News), is pleased to announce that its wholly- owned subsidiary FV Pharma Inc ("FV Pharma") have entered into a strategic alliance with SciCann Therapeutics Inc. ("SciCann") by executing a binding Memorandum of Understanding  (the "MOU") dated May 28, 2018, pursuant to which FV Pharma shall invest up to $3M in SciCann for a 15% equity stake. In addition, FV Pharma will receive an exclusive license in Canada for the production and distribution of a line of proprietary cannabinoid-based, patent pending and indication-specific products developed by SciCann. Under the MOU, FV Pharma shall receive premium access to the cannabinoid scientific research platform developed by SciCann in Israel, which includes a network of leading researchers, academic institutions and medical centers.

  • Newsfile2 months ago

    CSE New Listing - FSD Pharma Inc. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - June 1, 2018) - FSD Pharma Inc. (CSE: HUGE) is one of the latest new listings on the Canadian Securities Exchange. FSD Pharma is a Canadian cannabis company focused on building the world's largest indoor hydroponic cultivation and processing facility through its wholly owned subsidiary FV Pharma Inc., a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations ("ACMPR").InvestmentPitch Media has produced a "video" which provides ...

  • History Made, FSD Broke All-time Daily Volume Record
    CNW Group2 months ago

    History Made, FSD Broke All-time Daily Volume Record

    TORONTO, May 31, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE), is pleased to report that on its first day of trading (May 29, 2018) the company traded exactly 78,477,861 Class B subordinate voting shares on the CSE (Canadian Securities Exchange), 7,592,500 on AQC-Lit, 1,680,000 on AQC-Neo, 136,000 on CHIX, 236,500 on CX2 and 25,013,000 on the TriAct exchange for an aggregate total of 113,135,861 shares traded. FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour's drive from Toronto, FSD Pharma's management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world.

  • CNW Group2 months ago

    All-Time Daily Volume Record Broken and Thanks to All Shareholders

    TORONTO, May 30, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE:HUGE), is pleased to report that on its first day of trading (May 29, 2018) the company traded exactly 78,477,861 Class B subordinate voting shares on the CSE (Canadian Securities Exchange), 7,592,500 on AQC-Lit, 1,680,000 on AQC-Neo, 136,000 on CHIX, 236,500 on CX2 and 25,013,000 on the TriAct exchange for an aggregate total of 113,135,861 shares traded. FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour's drive from Toronto, FSD Pharma's management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world.